CSG Deepens Chemical Supply Lines and Showcases New Armour, Yet Shares Remain Under the Gun
Veröffentlicht: 03.06.2026 um 06:04 Uhr, Redaktion boerse-global.de
Czechoslovak Group is executing a quiet but determined strategy to secure its supply chain from raw material to finished weapon system, even as the market continues to punish its shares. This week alone, the Czech defence conglomerate has strengthened its grip on a critical artillery-grade chemical precursor and rolled out its latest generation of armoured vehicles in front of a domestic military audience – neither of which has managed to calm investor nerves.
A stealthy bet on Alzchem
The group has pushed its economic exposure in German speciality chemicals group Alzchem above the 20% threshold, combining a direct voting stake with derivatives. Through its subsidiary STALUNA TRADE, CSG now holds 9.9% of Alzchem's voting rights directly, while Total Return Swaps covering roughly 10.2% bring the total economic interest to just over a fifth of the capital. The swaps mature in May 2027.
The rationale is straightforward. Alzchem produces Nitroguanidine, a compound used in munitions and propellant charges. For CSG, which is rapidly scaling its artillery-shell output across Central and Eastern Europe, control over such inputs is a key step in vertical integration. Officially, the group describes itself as a long-term financial investor. Alzchem has confirmed it is in dialogue with all shareholders and said the transaction does not involve any changes to its management or supervisory board.
Should investors sell immediately? Or is it worth buying CSG?
Armour and all-wheel drive on display
On a separate track, CSG is using the Land Forces Day Bahna 2026 event near Strašice to put its land systems front and centre. The centrepiece is the Pandur 8×8 EVO, a new-generation wheeled armoured vehicle shown publicly for the first time by Tatra Defence. It can be configured as a combat, command, communication, fire-support, air-defence or engineer vehicle. At Bahna it appears as an armoured personnel carrier with a remote weapon station and a 30mm cannon.
Alongside the Pandur, Tatra Trucks is presenting the modernised Tatra 810M Tactic, an all-wheel-drive military truck payload of up to 5.2 tonnes, and two third-generation Tatra Force vehicles destined for the Czech army – one as a hook-loader, the other as a flatbed. Excalibur Army rounds out the display with the Patriot 4×4 modular platform, designed for combat, patrol, reconnaissance, command, medical and weapons-carrier roles.
The event is not tied to any new orders – CSG has not disclosed fresh contract values, delivery schedules or margin contributions – but it underscores the group's effort to raise the profile of land systems as a separate growth driver beyond its well-known munitions capacity.
Operational strength, market weakness
Both moves come as CSG continues to deliver strong financial results. In the first quarter of 2026, revenue rose to €1.544 billion, up 13.8% year-on-year. Net profit surged 83% to €299 million, while operating EBIT climbed 8.7% to €372 million. The net profit margin improved from 12% to 19%.
The order book hit a record €17 billion, with a further €27 billion in projects under negotiation. Net debt stood at €2.228 billion, or 1.3 times trailing twelve-month EBITDA. Management confirmed its full-year guidance: revenue between €7.4 billion and €7.6 billion and an adjusted EBIT margin of 24% to 25%.
CSG at a turning point? This analysis reveals what investors need to know now.
Yet the stock tells a different story. CSG shares closed at €15.95, down 3.9% on the day, and have shed nearly 16% over the past week. At that level, the stock is trading barely above its 52-week low of €15.73 and roughly 21% below its 50-day moving average of €20.40. The 52-week high of €33.81 is now more than 50% away.
Analysts remain optimistic nonetheless. Ten rate the shares a buy, none a sell. The consensus 12-month target stands at €32.45, implying more than double the current price. The stock trades on a forward P/E of 16, a deep discount to the European defence sector average of 23.
What comes next
For CSG, the near-term focus is whether the Alzchem derivatives will be converted into direct voting rights when they mature in May 2027 – a move that would further cement its control over a crucial raw material. For investors, the question is whether the operational strength and strategic positioning will eventually outweigh the selling pressure that has kept the shares pinned near their lows. The Bahna showcase, for now, provides visibility but no immediate catalyst. The next hard test will come when order intake from the land systems division begins to show up in the book.
Ad
CSG Stock: New Analysis - 3 June
Fresh CSG information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
